Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 805 Carcinoma, Non-Small-Cell Lung 767 Breast Neoplasms 731 Neoplasm Metastasis 340 Colorectal Neoplasms 339 Prostatic Neoplasms 324 Multiple Myeloma 309 Melanoma 305 Recurrence 237 Ovarian Neoplasms 236 Leukemia, Myeloid, Acute 236 Lymphoma, Non-Hodgkin 213 Lung Neoplasms 211 Carcinoma, Renal Cell 200 Lymphoma 189 Lymphoma, Follicular 163 Pancreatic Neoplasms 157 Leukemia, Lymphocytic, Chronic, B-Cell 149 Carcinoma, Hepatocellular 140 Stomach Neoplasms 137 Leukemia 133 Head and Neck Neoplasms 128 Lymphoma, Large B-Cell, Diffuse 126 Parkinson Disease 4, Autosomal Dominant Lewy Body 119 Squamous Cell Carcinoma of Head and Neck 110 Urinary Bladder Neoplasms 109 Carcinoma 101 Small Cell Lung Carcinoma 99 Triple Negative Breast Neoplasms 97 Glioblastoma 96

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has results × mCRPC × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡